Saints Capital to Acquire Interests in Fifty-Four Companies From Boston Scientific Corporation

SAN FRANCISCO, CA--(Marketwire - June 19, 2008) - Saints Capital, a leading secondary direct investment firm, today announced that it has signed a definitive agreement to acquire interests in fifty-four companies from Boston Scientific Corporation, (NYSE: BSX), a worldwide developer, manufacturer and marketer of medical devices.

"Boston Scientific has made a number of investments in high quality companies and we are excited to have the opportunity to acquire these interests from them," said Ken Sawyer, managing director of Saints Capital. "Acquiring investments in fifty-four companies in one fell-swoop is a complicated task, and we're proud of our ability to deliver the solution required for this transaction in an efficient manner that meets the needs of both Boston Scientific and the individual portfolio companies."

Saints is the leading global investment firm solely focused on the acquisition and management of venture capital portfolios on a secondary basis. These activities assist sellers who are seeking to obtain immediate liquidity for their investment stakes or to minimize future investment requirements in private equity. Saints remains committed to partnering with sellers to meet their objectives while providing portfolio companies with the necessary follow-on capital and a stable, long-term committed investor base.

In conjunction with the transaction, Scott Halsted, formerly a managing director at Morgan Stanley Venture Partners, will be joining Saints as a managing director focused on managing the assets acquired from Boston Scientific. "The medical device industry requires a high level of specialization for the effective evaluation and management of investments. In looking at this acquisition, we are very optimistic in the potential for growth opportunities for this portfolio of companies," said Halsted. "We believe that investment success comes from assisting portfolio companies in building value over the long term. In that light, we look forward to bringing the collective resources of the Saints team and extended global network to bear for these newly acquired companies as they expand their own businesses."

Saints has a proven track record of healthcare sector expertise, having been active investors in companies such as Arcadia Biosciences, Acorda Therapeutics, Cardiac Pathways, Coapt, Corus Pharma, ECIN, Emageon, eMedicine, GMP, Illumina, Laureate Pharma, LifeMasters, Locus Pharmaceuticals, Medicines, Medsite, MedVantx, Nitromed Notal Vision, PatientKeeper, Provation, Rita Medical, and Zonare.

Saints has over $1 billion of committed capital across eleven funds, through which Saints has acquired secondary investment interests in over 170 companies. Saints plans to provide follow-on capital as appropriate across the portfolio.

About Saints Capital

Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. Saints also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Saints is headquartered in San Francisco, with investment professionals throughout Europe and Asia. Saints currently manages funds with investments in more than 100 individual companies totaling more than $1 billion in originally invested capital. www.saintsvc.com

Contact Information: Contact: Saints Capital Melissa Biles and Jesse Odell LaunchSquad 415-625-8555 saints(a)launchsquad(dot)com